Free Trial

Evotec (OTCMKTS:EVTCY) Stock Price Crosses Above 50 Day Moving Average - What's Next?

Evotec logo with Medical background

Evotec SE (OTCMKTS:EVTCY - Get Free Report) shares passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $3.63 and traded as high as $4.16. Evotec shares last traded at $4.08, with a volume of 340,874 shares changing hands.

Evotec Trading Up 3.0%

The business's 50 day simple moving average is $3.64 and its two-hundred day simple moving average is $4.31. The stock has a market cap of $1.34 billion, a P/E ratio of 9.90 and a beta of 0.98. The company has a quick ratio of 2.50, a current ratio of 2.57 and a debt-to-equity ratio of 0.53.

Evotec Company Profile

(Get Free Report)

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties.

Featured Articles

Should You Invest $1,000 in Evotec Right Now?

Before you consider Evotec, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.

While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

4 Biotech Stocks on the Verge of Massive Breakthroughs
New AI Deals Just Sent These 4 Infrastructure Stocks Soaring
7 Nuclear Stocks One Announcement Away from Exploding

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines